Cyclerion Therapeutics Inc
$ 1.39
0.00%
05 Mar - close price
- Market Cap 4,719,700 USD
- Current Price $ 1.39
- High / Low $ 1.50 / 1.31
- Stock P/E N/A
- Book Value 2.58
- EPS -0.70
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.25 %
- 52 Week High 3.79
- 52 Week Low 1.03
About
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$8.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-05 | 2025-05-05 | 2025-03-03 | 2024-11-11 | 2024-08-07 | 2024-05-07 | 2024-03-05 | 2023-11-13 | 2023-07-28 | 2023-05-12 | 2023-03-22 |
| Reported EPS | -0.3 | -0.11 | -0.5591 | 0.2082 | -0.2862 | -0.5267 | -0.6183 | -0.6847 | 3.1072 | -1.8322 | -3.1957 | -0.17 |
| Estimated EPS | 0 | None | None | None | None | None | None | None | None | -0.28 | -0.3 | -0.29 |
| Surprise | -0.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.5522 | -2.8957 | 0.12 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | -554.3571% | -965.2333% | 41.3793% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CYCN
2026-03-04 13:51:49
This article provides a detailed historical overview of Cyclerion Therapeutics Inc.'s (NASDAQ: CYCN) quarterly earnings, including EPS and revenue actuals, analyst estimates, and surprise percentages. It also outlines the upcoming earnings date and estimates for Q4 2025. The report details quarterly performance trends for EPS and revenue, emphasizing historical quarter-over-quarter growth and acceleration, and addresses frequently asked questions regarding past earnings reports.
2026-02-28 17:51:49
This page provides news and event updates for Cyclerion Therapeutics (CYCN). Recent news highlights include positive FDA feedback for its lead program CYC-126, an exclusive collaboration with Medsteer, and a licensing deal with MIT for its strategic relaunch in neuropsychiatric conditions. The company is focusing on developing CYC-126 for treatment-resistant depression with a Phase 2 trial expected to start in late 2026.
2026-02-27 21:52:27
Cyclerion Therapeutics Inc. is projected to report an earnings loss of 38 cents per share. This information comes from a Refinitiv earnings preview. The article provides no further details beyond this forecast.
2026-02-26 14:53:02
The average one-year price target for Cyclerion Therapeutics (CYCN) has been increased by 100% to $8.16 per share, up from $4.08. This new target represents a 518.18% increase from its last closing price of $1.32. Institutional ownership in CYCN has seen an increase in total shares owned, despite a decrease in the number of reporting funds.
2026-02-25 15:52:27
This article provides a detailed financial overview of Cyclerion Therapeutics Inc (CYCN), including its income statement, balance sheet, and cash flow information. It highlights key financial metrics for fiscal year 2024, such as $2.0M in revenue, a net loss of -$3.1M, and an operating margin of -181.4%. The company's financial health is rated as weak by the Piotroski F-Score (3/9), and its earnings quality is deemed low at 1.42x, suggesting accrual-driven earnings rather than cash generation.
2026-02-23 14:52:33
Cyclerion Therapeutics (CYCN) has received positive feedback from the U.S. FDA regarding its planned Phase 2 proof-of-concept study for CYC-126 in treatment-resistant depression (TRD). The company also announced the formation of a Clinical Advisory Board and has selected a contract research organization, anticipating the trial to initiate in the second half of 2026. This therapy is a novel anesthetic-based investigational treatment for TRD.
